Cancer Prevention Research · 2014 · 40 citations · 21 references
MedicineDermatologyPharmacologyCancer PreventionCutaneous OncologyGenodermatosesBasal Cell CarcinomaMalignant NeoplasmsNeoplastic Skin LesionsSkin Cancer PreventionSkin TumorsHigh-risk Cutaneous CarcinomaManagement Of High-risk PatientsMurine ModelsOpen-label TrialsRelative SpecificityRetinoid ReceptorsRetinoid X ReceptorsTopical Retinoid Therapy
Sporadic human basal cell carcinomas (BCC) are generally well managed with current surgical modalities. However, in the subset of high-risk patients predisposed to developing large numbers of BCCs, there is an unmet need for effective, low-morbidity chemoprevention. This population includes fair-skinned patients with extensive sun exposure and those with genodermatoses such as the basal cell nevus (Gorlin) syndrome (BCNS). Tazarotene (Tazorac, Allergan) is a topical retinoid with relative specificity for RAR-β and RAR-γ receptors. We previously demonstrated tazarotene's robust anti-BCC efficacy in Ptch1(+/-) mice, a murine equivalent of BCNS, and others have found it to have some efficacy against sporadic human BCCs. We report here results of a randomized, double-blind, vehicle-controlled study in patients with BCNS evaluating the efficacy of topically applied tazarotene for BCC chemoprevention (N = 34 subjects), along with an open-label trial evaluating tazarotene's efficacy for chemotherapy of BCC lesions (N = 36 subjects) for a maximum follow-up period of 3 years. We found that only 6% of patients had a chemopreventive response and that only 6% of treated BCC target lesions were clinically cured. Our studies provide no evidence for either chemopreventive or chemotherapeutic effect of tazarotene against BCCs in patients with BCNS.
21
Jan Nico Bouwes Bavinck, L. M. Tieben, Fokko J. van der Woude et al. · Journal of Clinical Oncology · 1995 · 404 citations